# Tfcp2l1 as a central integrator of hypoxia, dedifferentiation, and tumor progression

## TL;DR

Tfcp2l1 is a key gene that connects low oxygen conditions in tumors to cancer cell dedifferentiation and progression, potentially offering new treatment targets.

## Contribution

This paper identifies Tfcp2l1 as a central integrator linking hypoxia, dedifferentiation, and tumor progression in cancer.

## Key findings

- Tfcp2l1 reactivates in cancers under hypoxia, promoting dedifferentiation and stem cell-like properties.
- Its expression is associated with poor prognosis and tumor aggressiveness across multiple cancer types.
- Tfcp2l1 regulates transcriptional networks that suppress differentiation and support self-renewal in cancer cells.

## Abstract

The gene Tfcp2l1 has emerged as a central player linking key processes in cancer biology: hypoxia, immortalization, dedifferentiation, and tumor progression. Originally identified for its role in maintaining pluripotency in embryonic stem cells, Tfcp2l1 has been found to reappear in various cancers, especially under conditions of low oxygen (hypoxia). Hypoxia, a common feature of solid tumors, triggers the reactivation of developmental genes like Tfcp2l1, enabling cancer cells to dedifferentiate and adopt stem cell-like properties. This dedifferentiation facilitates the immortalization of cells—allowing them to bypass senescence and continue proliferating. Tfcp2l1 contributes to this process by regulating transcriptional networks that suppress differentiation and support self-renewal. Its expression correlates with poor prognosis in several cancers, highlighting its potential role in tumor aggressiveness and resistance to therapy. By acting at the intersection of cellular plasticity, stress adaptation, and oncogenic transformation, Tfcp2l1 may serve as a molecular bridge linking early developmental programs with malignant behaviors. Understanding how Tfcp2l1 integrates signals from hypoxic stress and drives dedifferentiation could uncover new therapeutic targets aimed at reversing or halting tumor progression.

The online version contains supplementary material available at 10.1186/s13046-025-03501-9.